Biotechnology Pfizer’s Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study – Pfizer (NYSE:PFE) Read more
Biotechnology FDA Approves Pfizer’s Leukemia Drug For Kids As Old As One Year – Pfizer (NYSE:PFE) Read more
Biotechnology Pfizer’s Respiratory Syncytial Virus Vaccine Maintains Staying Power In Older Adults Through 2nd RSV season, Study Finds – Pfizer (NYSE:PFE) Read more
Biotechnology Pfizer’s Mixed Bag: A Look At The Fourth Quarter 2023 Earnings Call – Main Takeaways – Pfizer (NYSE:PFE) Read more
Biotechnology Pfizer’s COVID-19 Treatment Paxlovid Will No Longer Be Available For Emergency Use After This Date, FDA Revises Label – Pfizer (NYSE:PFE) Read more